Related Experiment Video
Updated: Mar 28, 2026

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Low High-Density Lipoprotein and Risk of Myocardial Infarction
1University of California, Riverside, School of Medicine, Riverside, CA, USA. ; Riverside Medical Clinic, Riverside, CA, USA.
Insights
Low levels of high-density lipoprotein (HDL) cholesterol are a significant risk factor for myocardial infarction. This review covers HDL
Area of Science:
- Cardiology
- Lipid Metabolism
- Cardiovascular Disease Research
Background:
- Low high-density lipoprotein (HDL) cholesterol is an established independent risk factor for myocardial infarction (MI).
- Understanding HDL's role in cardiovascular health is crucial for developing effective prevention strategies.
Purpose of the Study:
- To review current knowledge on high-density lipoprotein (HDL).
- To explore the association between low HDL and myocardial infarction (MI).
- To discuss HDL-targeted therapies and emerging treatments.
Main Methods:
- Literature review of studies on HDL structure, function, and subclasses.
- Analysis of clinical trials investigating HDL-targeted therapies.
- Discussion of novel pharmacological agents for HDL modulation.
Main Results:
- Low HDL cholesterol is a confirmed independent risk factor for myocardial infarction.
- Various HDL subclasses exhibit distinct functionalities.
- Emerging therapies show potential for modulating HDL levels and cardiovascular risk.
Conclusions:
- Low HDL cholesterol significantly contributes to myocardial infarction risk.
- Further research into HDL-targeted therapies, including novel agents like alirocumab and evolocumab, is warranted.
- Comprehensive understanding of HDL metabolism is key to advancing cardiovascular disease prevention.
Abstract:
Low HDL is an independent risk factor for myocardial infarction. This paper reviews our current understanding of HDL, HDL structure and function, HDL subclasses, the relationship of low HDL with myocardial infarction, HDL targeted therapy, and clinical trials and studies. Furthermore potential new agents, such as alirocumab (praluent) and evolocumab (repatha) are discussed.
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease I: Introduction
Lipids: Dietary Sources and Requirements

